-
MLKL Polymerization and Lysosomal Permeabilization
2026-09-15
This study identifies lysosomal membrane permeabilization as a major execution step in necroptosis initiated by polymerized MLKL. Using live-cell imaging, MLKL-domain experiments, and cathepsin B perturbation, the authors connect lysosomal damage to cytosolic protease release and subsequent cell death.
-
TCF25, Lysosomal Acidification, and Glucose Starvation
2026-09-15
Ren et al. identify TCF25 as a nutrient-stress regulator that connects glucose starvation to V-ATPase-dependent lysosomal acidification, autophagy, and eventual lysosome-dependent cell death. The study provides a mechanistic framework for distinguishing adaptive recycling from maladaptive ferritinophagy during metabolic and ischemic stress.
-
Silymarin Workflows for Reproducible Research
2026-09-14
Build more interpretable oxidative-stress, hepatocellular carcinoma, metabolic, and antiviral experiments with a mixture-aware Silymarin workflow. This guide combines solvent control, dose-ranging, orthogonal readouts, and chemistry-informed troubleshooting to distinguish true biology from precipitation, vehicle effects, and assay interference.
-
Tetrazolium (chloride) Workflows for Tissue Viability
2026-09-14
Tetrazolium (chloride), also called Tetrazolium Red, converts dehydrogenase activity into a visible formazan signal for cell and ischemic-tissue analysis. This guide links practical assay setup with the cardamomin stroke study, emphasizing quantitative workflow design, controls, and interpretation limits.
-
Deferasirox Fe3+ Chelate in Translational Iron Research
2026-09-13
Deferasirox Fe3+ chelate offers translational researchers a defined ferric-iron complex for investigating iron overload, mitochondrial ROS, NF-κB signaling, and myeloid differentiation. This article connects beta-thalassemia iron chelation and chronic anemia iron management with the stage-specific biology reported for deferasirox, while outlining controls that distinguish iron removal from redox-driven cell-state effects.
-
HRP Goat Anti-Rabbit IgG (H+L) Antibody
2026-09-12
K1223 is an HRP-labeled, affinity-purified polyclonal secondary antibody for detecting rabbit IgG primary antibodies in Western blotting, ELISA, IHC, and ICC. It is intended for research workflows that require rabbit IgG detection and should not be treated as a diagnostic reagent or used without assay-specific validation.
-
Panobinostat (LBH589): From Chromatin to Cell Stress
2026-09-12
A translational perspective on how Panobinostat (LBH589) connects broad-spectrum HDAC inhibition with apoptosis, treatment resistance, and proteotoxic stress. The article combines product intelligence with findings from a recent rencofilstat–ixazomib study to guide model selection, mechanistic validation, combination design, and future oncology research.
-
40-Hz Flicker and Retinal Amyloid Clearance
2026-09-11
A 2026 mouse study links 40-Hz light flicker to enhanced retinal amyloid-β clearance through regulation of MHC-II-positive microglia. The combination of molecular, histologic, and visual-function assays, together with minocycline-based microglial inhibition, provides a useful framework for testing whether immune-cell activity contributes to retinal waste removal.
-
How Damaged CNS Myelin Remodels Before Loss
2026-09-11
Arafa et al. show that myelin swelling is an early, dynamic response to central nervous system damage and does not inevitably result in sheath loss. Across zebrafish, rodent, and human tissue, the study identifies neuronal activity as a modifiable factor that can worsen swelling, while also revealing a potential window for preserving or repairing compromised myelin.
-
Primidone: A Target-Aware Translational Framework
2026-09-10
Primidone (Mysoline) can serve as more than a repurposed antiepileptic: it is a target-aware probe spanning TRPM3, RIPK1, and translational biomarkers. This guide connects molecular assay design with ALS evidence while clarifying exposure, selectivity, and disease-model limitations.
-
DMH1: An ALK2 Inhibitor for Organoid Assays
2026-09-10
DMH1 is an ALK2 inhibitor that can serve as a pathway-resolved probe in pancreatic ductal organoids and NSCLC models. This article explains how to separate organoid formation, lineage composition, and cancer phenotypes when interpreting BMP pathway perturbation.
-
2-Hydroxypropyl-β-cyclodextrin Protocol Guide
2026-09-09
2-Hydroxypropyl-β-cyclodextrin is a water-soluble cyclic oligosaccharide used to screen and improve the aqueous handling of poorly soluble hydrophobic compounds, particularly molecules with aromatic or phenyl groups. This dossier-based guide supports pharmaceutical and biochemical formulation workflows, but increased solubility should not be interpreted as proof of therapeutic efficacy, bioavailability, or suitability outside validated applications.
-
Methylprednisolone: Inflammation and Bone Models
2026-09-09
Methylprednisolone is a synthetic glucocorticoid receptor agonist used to interrogate cytokine control and glucocorticoid-associated skeletal injury. Its reported inhibition of TNF-alpha, modulation of NF-kappaB signaling, and defined rat-model parameters support reproducible research, but they do not establish clinical efficacy for bone preservation.
-
MALAT1–miR-125b–STAT3 Axis in Sepsis
2026-09-08
The reference study identifies a MALAT1–miR-125b–STAT3 regulatory axis that increases procalcitonin expression in sepsis-associated models. Its combination of clinical samples, LPS-stimulated U937 cells, RNA localization, interaction assays, and protein measurements provides a mechanistic framework for interpreting how a diagnostic biomarker may be regulated, while leaving clinical validation and in vivo causality unresolved.
-
Light-Inducible RNA Release for Regulated Gene Therapy
2026-09-08
The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that controls therapeutic gene expression at the translation stage. Its compatibility with AAV delivery, light-sensitive cell systems, and tissue-accessible illumination suggests a practical route toward reversible gene therapies for metabolic and retinal disorders.